For your adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment
HELP RAISE AND MAINTAIN PLATELET COUNTS1
Patients on DOPTELET® (avatrombopag) obtained a platelet count of ≥50×109/L for a median of
12.4 weeks without the need for rescue therapy (P<.0001 vs placebo)*†
of patients treated with DOPTELET achieved platelet counts of ≥50×109/L on Day 81§
*Study Design: Efficacy was evaluated in a 6-month, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. Patients had previously received one or more prior chronic ITP therapies and had average screening and baseline platelet counts of <30×109/L. Forty-nine patients were randomized (2:1) to receive either DOPTELET (n=32) or placebo (n=17).
†The primary efficacy endpoint was the cumulative number of weeks of platelet response, defined as a platelet count ≥50×109/L in the absence of rescue therapy, over 6 months of once-daily treatment in adults with chronic ITP.
‡Target platelet count window in pivotal trial was ≥50×109/L to ≤150×109/L.
§A secondary efficacy endpoint was the proportion of patients with a platelet response (platelet count ≥50×109/L) at Day 8.
1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.
2. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490.
3. Data on file. Dova Pharmaceuticals, Inc.